15.75
-0.27 (-1.69%)
| Previous Close | 16.02 |
| Open | 15.45 |
| Volume | 1,860,641 |
| Avg. Volume (3M) | 1,783,577 |
| Market Cap | 1,608,279,808 |
| Price / Book | 5.69 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 20 Aug 2025 |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Biohaven Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.75 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Dec 2024 | 5,620,271 |
| Bellevue Group Ag | 31 Dec 2024 | 2,040,853 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 57.00 (Baird, 261.91%) | Buy |
| Median | 55.00 (249.21%) | |
| Low | 21.00 (RBC Capital, 33.33%) | Hold |
| Average | 44.33 (181.46%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 17.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 18 Jun 2025 | 55.00 (249.21%) | Buy | 14.39 |
| RBC Capital | 19 May 2025 | 21.00 (33.33%) | Hold | 15.75 |
| 13 May 2025 | 54.00 (242.86%) | Buy | 19.51 | |
| Baird | 28 Apr 2025 | 57.00 (261.90%) | Buy | 21.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |